Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment

Background The World Health Organization (WHO) HIV drug resistance (HIVDR) threshold survey method was developed for surveillance of transmitted HIVDR in resource-limited countries. The method is being implemented with minimal resources as a routine public health activity to produce comparable results in multiple countries and areas within countries. Transmitted drug resistant HIV strains will be seen first in cities or health districts where antiretroviral treatment (ART) has been widely available for years. WHO recommends countries begin surveillance in these areas. Methods Each survey requires ≤47 specimens from individuals consecutively diagnosed with HIV to categorize resistance to each relevant drug class as <5%, 5–15% or >15%. Use of routinely collected information and remnant specimens is recommended to minimize costs. Site and individual eligibility criteria are designed to minimize inclusion of ARV-experienced individuals and individuals infected before ART was available. Results Surveys have been implemented in 21 countries. In this supplement, seven countries report results of <5% transmitted HIVDR in areas where ART has been available for the longest time period. The main challenges in implementation are acquiring sufficient numbers of eligible specimens and optimizing specimen handling. Conclusion The WHO HIVDR threshold survey method is feasible in resource-limited countries and produces information relevant to ART and drug resistance prevention planning.

[1]  Bluma G. Brenner,et al.  Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection , 2002, Journal of Virology.

[2]  D. Bennett,et al.  HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam , 2008, Antiviral therapy.

[3]  Scaling up priority HIV / AIDS interventions in the health sector JUNE 2008 , 2008 .

[4]  C. Mahé,et al.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? , 2002, AIDS.

[5]  J. Fellay,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[6]  Sally Blower,et al.  Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. , 2003, Current drug targets. Infectious disorders.

[7]  F. Antunes,et al.  Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen , 2007, AIDS.

[8]  Neil M Ferguson,et al.  Modelling the Impact of Antiretroviral Use in Resource-Poor Settings , 2006, PLoS medicine.

[9]  M. Weinstein,et al.  The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  R. Black,et al.  Lot quality assurance sampling techniques in health surveys in developing countries: advantages and current constraints. , 1991, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[11]  E. Schouten,et al.  Early warning indicators for HIV drug resistance in Malawi , 2008, Antiviral therapy.

[12]  Simon D W Frost,et al.  Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. , 2003, The Journal of infectious diseases.

[13]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[14]  J. Church,et al.  ANTIRETROVIRAL-DRUG RESISTANCE AMONG PATIENTS RECENTLY INFECTED WITH HIV , 2003, Pediatrics.

[15]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[16]  Elena Losina,et al.  Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness , 2001, Annals of Internal Medicine.

[17]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[18]  J. Kahn,et al.  Predicting the transmission of drug-resistant HIV: comparing theory with data. , 2003, The Lancet. Infectious diseases.

[19]  G. Rutherford,et al.  Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda , 2006, AIDS.

[20]  D. Bennett,et al.  The World Health Organization's global strategy for prevention and assessment of HIV drug resistance , 2008, Antiviral therapy.

[21]  S Lemeshow,et al.  Lot quality assurance sampling: single- and double-sampling plans. , 1991, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[22]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[23]  M. Holstad,et al.  Motivating HIV positive women to adhere to antiretroviral therapy and risk reduction behavior: the KHARMA Project. , 2006, Online journal of issues in nursing.

[24]  K. D. de Cock,et al.  HIV prevention for a threatened continent: implementing positive prevention in Africa. , 2006, JAMA.

[25]  D. Bennett,et al.  World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites , 2008, Antiviral therapy.

[26]  M. Youle,et al.  Economic implication of HIV-1 resistance testing in overall clinical care , 2004 .

[27]  T. F. Rinke de Wit,et al.  Implementation of an Antiretroviral Access Program for HIV-1-Infected Individuals in Resource-Limited Settings: Clinical Results From 4 African Countries , 2007, Journal of acquired immune deficiency syndromes.

[28]  B. Chi,et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.

[29]  W. Heneine,et al.  Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. , 2000, The Journal of infectious diseases.

[30]  Raffaele Vardavas,et al.  The Emergence of HIV Transmitted Resistance in Botswana: “When Will the WHO Detection Threshold Be Exceeded?” , 2007, PloS one.

[31]  W. Hladik,et al.  Prevention of mother-to-child transmission and voluntary counseling and testing programme data: what is their utility for HIV surveillance? , 2005, AIDS.

[32]  S. Deeks,et al.  Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.

[33]  Richard D Moore,et al.  Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. , 2006, American journal of epidemiology.

[34]  P. Wright,et al.  Antiretroviral therapy in a thousand patients with AIDS in Haiti. , 2005, The New England journal of medicine.

[35]  L. Torian,et al.  Characteristics of Persons With Recently Acquired HIV Infection: Application of the Serologic Testing Algorithm for Recent HIV Seroconversion in 10 US Cities , 2007, Journal of acquired immune deficiency syndromes.

[36]  H. Moffat,et al.  Two and a Half Years of Routine HIV Testing in Botswana , 2007, Journal of acquired immune deficiency syndromes.

[37]  P. Kaleebu,et al.  Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa , 2006, AIDS.

[38]  T. Brown,et al.  New strategies for HIV surveillance in resource-constrained settings: an overview. , 2005, AIDS.

[39]  D. Bennett,et al.  Darunavir: pharmacokinetics and drug interactions. , 2008 .

[40]  E. Rosenberg,et al.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection. , 1999, JAMA.

[41]  L. Ivers,et al.  Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  Deenan Pillay,et al.  Current Patterns in the Epidemiology of Primary HIV Drug Resistance in North America and Europe , 2004, Antiviral therapy.

[43]  Soo-Yon Rhee,et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.

[44]  P. Sonnenberg,et al.  Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up , 2007, AIDS.

[45]  S. Gove,et al.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.

[46]  W. Keulen,et al.  Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. , 1996, The EMBO journal.

[47]  Erin N. Bodine,et al.  The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. , 2005, AIDS.

[48]  M. Sweat,et al.  The impact of HIV treatment on risk behaviour in developing countries: A systematic review , 2007, AIDS care.

[49]  Z. Grossman,et al.  Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia , 2007, Antiviral therapy.

[50]  Soo-Yon Rhee,et al.  Consensus Drug Resistance Mutations for Epidemiological Surveillance: Basic Principles and Potential Controversies , 2008, Antiviral therapy.

[51]  D. Bennett,et al.  Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues. , 2008 .

[52]  H. Gershengorn,et al.  Predicting the unpredictable: Transmission of drug-resistant HIV , 2003, Nature Medicine.

[53]  K. Kamoto,et al.  Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi , 2007, Antiviral therapy.

[54]  K. D. de Cock,et al.  Unfinished business--expanding HIV testing in developing countries. , 2006, The New England journal of medicine.

[55]  D. Pillay,et al.  World Health Organization/HIVResNet Drug Resistance Laboratory Strategy , 2008, Antiviral therapy.

[56]  D. Bennett,et al.  A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings , 2008, Antiviral therapy.

[57]  C. Gilks,et al.  National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? , 2006, AIDS.

[58]  D. Bennett,et al.  Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006 , 2008, Antiviral therapy.

[59]  D. Bennett,et al.  Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania , 2008, Antiviral therapy.

[60]  K. Ruxrungtham,et al.  HIV drug resistance transmission threshold survey in Bangkok, Thailand , 2008, Antiviral therapy.

[61]  Kara Wools-Kaloustian,et al.  Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya , 2006, AIDS.

[62]  V. Johnson,et al.  Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation , 2004, Journal of acquired immune deficiency syndromes.

[63]  R Brookmeyer,et al.  Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence , 2000, AIDS.

[64]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[65]  Lanata Cf,et al.  Lot quality assurance sampling techniques in health surveys in developing countries: advantages and current constraints. , 1991 .

[66]  J. Fisher,et al.  First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. , 2002, AIDS.

[67]  N. Ford,et al.  Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand , 2007, AIDS.

[68]  C. Pettinelli,et al.  Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter , 1996 .

[69]  F. Mammano,et al.  HIV drug resistance and viral fitness. , 2000, Advances in pharmacology.

[70]  A. Puren,et al.  Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004 , 2008, Antiviral therapy.

[71]  P. Kaleebu,et al.  Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of Combivir/Tenofovir within the DART Trial. , 2007 .